

BeyondSpring Starts China-US Phase III Trial of Lung Cancer Drug

publication date: Jun 29, 2016

BeyondSpring Pharma, a virtual New York city biopharma, has launched a China-US Phase III clinical trial of its lead drug, plinabulin. Plinabulin is a small-molecule infused drug that will be tested as an adjunct to docetaxel in patients with non-small cell lung cancer. According to BeyondSpring, plinabulin has dual anti-angiogenesis and immunotherapy mechanisms. The trial will enroll 550 patients: 440 in China and the rest in the US and Australia. Overall survival will be the primary endpoint.

<http://www.chinabiotoday.com/articles/20160629>